Neurocrine Biosciences, Inc. (NBIX) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Loading...

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices

Follow our journey and product updates

Product

Overview Company evaluations Research a topic

Company

About us Blog Contact

Legal

Terms Privacy Policy

Neurocrine Biosciences, Inc. (NBIX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Neurocrine Biosciences, Inc. (NBIX)

Company Performance

Current Price

as of Dec 03, 2024

$125.44

P/E Ratio

33.60

Market Cap

$12.7B

Description

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Metrics

Overview

HQSan Diego, CA
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerNBIX
Price$125.44-0.36%

Trading Information

Market cap$12.70B
Float97.32%
Average Daily Volume (1m)964,836
Average Daily Volume (3m)920,538
EPS$3.86

Company

Revenue$2.24B
Rev growth (1yr)24.72%
Net income$129.80M
Gross margin97.81%
EBITDA margin30.75%
EBITDA$191.30M

EV$11.08B
EV/Revenue4.94
P/E33.60
P/S5.83
P/B4.67

Documents

SEC Filings

8-K (2024-11-01)

8-K (2024-10-30)

8-K (2024-10-11)

8-K (2024-08-28)

8-K (2024-08-01)

8-K (2024-05-28)

8-K (2024-05-23)

8-K (2024-05-01)

8-K (2024-02-07)

8-K (2023-11-13)

8-K (2023-11-09)

8-K (2023-10-31)

8-K (2023-10-06)

8-K (2023-10-05)

8-K (2023-09-12)

8-K (2023-08-01)

8-K (2023-07-13)

8-K (2023-07-12)

8-K (2023-05-19)

8-K (2023-05-03)

8-K (2023-03-29)

8-K (2023-02-24)

8-K (2023-02-10)

8-K (2023-02-06)

8-K (2023-01-09)

10-Q (2024-10-30)

10-Q (2024-08-01)

10-Q (2024-05-01)

10-Q (2023-10-31)

10-Q (2023-08-01)

10-Q (2023-05-03)

10-K (2024-02-09)

10-K (2023-02-09)

Earnings Calls

Earnings Report 2024Q3

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report (2023-10-31)

Earnings Report (2023-08-01)

Factset

Factset Business Description

Factset Street Account

Neurocrine Biosciences provides pipeline update; ending further development of NBI-921352 in FOS, trial of NBI-1065846 misses primary endpoint ($112.15, 0.00) (2023-11-09T21:25:41Z)

Neurocrine Biosciences presents INGREZZA (valbenazine) capsules interim data ($111.54, 0.00) (2023-11-02T12:36:14Z)

Neurocrine Biosciences enters into INGREZZA patent litigation agreement with Lupin Pharmaceuticals - 8-K ($112.15, 0.00) (2023-11-09T22:57:15Z)

Neurocrine Biosciences announces settlement of INGREZZA Abbreviated New Drug Application (ANDA) litigation ($107.17, 0.00) (2023-11-13T12:03:12Z)

Neurocrine Biosciences announces phase 3 pediatric study results of crinecerfont in children and adolescents for the treatment of congenital adrenal hyperplasia met primary and key secondary endpoints ($110.69, 0.00) (2023-10-05T11:05:41Z)

Follow-up: Neurocrine Biosciences announces settlement of INGREZZA Abbreviated New Drug Application (ANDA) litigation - 8-K ($107.17, 0.00) (2023-11-13T12:05:12Z)

Wikipedia

Neurocrine_Biosciences_Inc